EUR/JPY stays muted around 184.00 as expectations for a BoJ rate increase grow
EUR/JPY Pauses After Four-Day Rally
The EUR/JPY currency pair has ended its four-day upward trend, hovering near 184.20 during Thursday’s European trading session. The Japanese Yen has strengthened, buoyed by increasing speculation that the Bank of Japan (BoJ) may raise interest rates soon. This sentiment is fueled by inflationary pressures linked to rising oil prices amid ongoing tensions in the Middle East, as central banks worldwide signal their willingness to tighten monetary policy in response to persistent inflation.
Although the BoJ maintained its policy rate in March, Governor Kazuo Ueda suggested that a rate adjustment could be considered in April. Japanese government bond yields have climbed, with the 10-year yield reaching 2.27% on Thursday after reversing a two-day decline. Short-term yields also surged, with 2-year bonds hitting their highest levels in thirty years and 5-year yields setting new records. This upward movement in yields reflects tighter financial conditions and mounting expectations for higher interest rates in Japan.
According to the minutes from the BoJ’s January meeting, policymakers agreed that additional rate hikes would be warranted if economic and inflation targets are achieved, given that real interest rates remain significantly negative. Most members advocated for a flexible approach, preferring to evaluate policy at each meeting rather than adhering to a predetermined schedule for tightening.
Potential Recovery for EUR/JPY
There is a possibility that EUR/JPY could rebound, as the Euro may gain support from optimism surrounding efforts to ease tensions in the Middle East. The White House has indicated that negotiations are ongoing, with reports that the Trump administration has sent a 15-point proposal to Iran through Pakistan.
Senior Iranian officials are currently reviewing the proposal but have shown reluctance to engage directly with the United States. Tehran is expected to reject the American ceasefire plan, instead presenting its own five-point initiative, which includes asserting sovereignty over the Strait of Hormuz.
ECB Response to Geopolitical Risks
European Central Bank (ECB) President Christine Lagarde stated that the ECB is closely monitoring the economic fallout from the conflict and stands ready to adjust its policy at any meeting should energy-related inflation risks intensify.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
